GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » Altman Z-Score

Viveve Medical (Viveve Medical) Altman Z-Score : -35.10 (As of May. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Viveve Medical has a Altman Z-Score of -35.10, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Viveve Medical's Altman Z-Score or its related term are showing as below:


Viveve Medical Altman Z-Score Historical Data

The historical data trend for Viveve Medical's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical Altman Z-Score Chart

Viveve Medical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.51 -5.92 -13.40 -21.10 -13.97

Viveve Medical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.34 -13.97 -18.70 -26.53 -34.70

Competitive Comparison of Viveve Medical's Altman Z-Score

For the Medical Devices subindustry, Viveve Medical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viveve Medical's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Viveve Medical's Altman Z-Score falls into.



Viveve Medical Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Viveve Medical's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.1014+1.4*-21.2699+3.3*-1.7469+0.6*0.0003+1.0*0.5616
=-35.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2022:
Total Assets was $12.15 Mil.
Total Current Assets was $9.60 Mil.
Total Current Liabilities was $10.84 Mil.
Retained Earnings was $-258.51 Mil.
Pre-Tax Income was -4.976 + -5.344 + -5.764 + -6.26 = $-22.34 Mil.
Interest Expense was -0.292 + -0.284 + -0.27 + -0.266 = $-1.11 Mil.
Revenue was 1.684 + 1.795 + 1.641 + 1.706 = $6.83 Mil.
Market Cap (Today) was $0.00 Mil.
Total Liabilities was $10.97 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(9.604 - 10.837)/12.154
=-0.1014

X2=Retained Earnings/Total Assets
=-258.514/12.154
=-21.2699

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-22.344 - -1.112)/12.154
=-1.7469

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.003/10.97
=0.0003

X5=Revenue/Total Assets
=6.826/12.154
=0.5616

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Viveve Medical has a Altman Z-Score of -35.10 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Viveve Medical  (OTCPK:VIVE) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Viveve Medical Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Viveve Medical's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Viveve Medical (Viveve Medical) Business Description

Traded in Other Exchanges
N/A
Address
345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
Executives
Presnell Sharon Collins director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta director 1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin officer: Chief Financial Officer PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson officer: CBO & President 150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller director, officer: CEO and Director 150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico director, 10 percent owner 16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc director, 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch director, 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney director, 10 percent owner PO BOX 7414, JACKSON WY 83002